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Abstract: With recent advances in genomic technologies,
candidate human disease genes are being mapped at an
accelerated pace. There is a clear need to move forward
with genetic tools that can efficiently validate these
mutations in vivo. Murine somatic mutagenesis is
evolving to fulfill these needs with tools such as somatic
transgenesis, humanized rodents, and forward genetics.
By combining these resources one is not only able to
model disease for in vivo verification, but also to screen
for mutations and pathways integral to disease progres-
sion and therapeutic intervention. In this review, we
briefly outline the current advances in somatic mutagen-
esis and discuss how these new tools, especially the
piggyBac transposon system, can be applied to decipher
human biology and disease.
Introduction
The recent revolution in high-throughput sequencing and
genomic technologies has enabled geneticists to rapidly map
disease susceptibility to genomic regions. As a result, there has
been an explosion in the number of candidate genes identified for
a multitude of human conditions [1]. We are now faced with the
daunting task of verifying candidate disease genes, deciphering
underlying mechanisms, and developing therapeutic strategies.
The ability to genetically manipulate the mouse to study and
model disease in vivo makes it an ideal tool to match the challenge.
Current and future application of genetic tools such as somatic
mosaicism, humanized rodents, and forward genetics will empow-
er interrogation of mammalian biology and disease in the coming
years. The ability to efficiently produce genetic mosaics facilitates
gene analysis in somatic cells, which will reduce the time and cost
that has been associated in producing germline models. Human-
ized rodents, which continue to evolve into better human models,
can be combined with genetic mosaic tools to dissect mechanisms
of human disease. Furthermore, the advent of forward genetic
screening strategies like in vivo RNAi and insertional mutagenesis
now allows investigators to identify novel players in mammalian
disease and developmental processes. With these new tools in
hand, investigators can use the mouse to rapidly identify key
pathways in disease pathogenesis for targeted therapies.
It has become increasingly clear that somatic alterations,
whether sequence changes or copy number variations, play a
prominent role in human disease and physiology. An obvious
example is cancer, where cells can be marked by hundreds of
somatic mutations, many of which likely drive the progression of
the disease [2,3]. Interestingly, somatic mutations can also revert
disease phenotypes, as illustrated recently in the case of ichthyosis
with confetti, which has allowed for the identification of the
causative mutation [4]. There are also established roles for somatic
mutations and the accompanying mosaicism in shaping the
defense repertoire of our immune system [5] and possibly creating
neuronal diversity [6–8]. Clearly, genetic mosaicism is an
important mechanism driving many developmental processes,
but in an aberrant context can cause disease. The advent of
genetic tools, which allow us to mirror somatic mosaicism by the
introduction of mutations temporally and spatially in distinct
populations of cells, provide a powerful means to study the cellular
interplay that shapes disease and developmental processes
(Table 1).
Rapid Dissection of Disease and Development in
the Mouse
One of the major drawbacks of mouse genetics is the time it
takes to generate germline transgenic or knockout lines and to
combine multiple alleles into the same background. Performing
experiments with somatic gene introduction has the potential to
dramatically enhance the speed and broaden the scope of such
experiments. Lentiviral- and transposon-mediated genetic manip-
ulation will likely be widely used moving forward, due to the
potential for genetically manipulating a variety of cell types and
stably integrating transgenes. Although targeted mutations cannot
be induced with these modalities, they can be introduced into lines
harboring traditional germline-targeted alleles, thus broadening
the utility of both systems.
Viral Vectors for Somatic Transgenesis
Integrating viral vectors like retrovirus or lentivirus have been
used to create genetic mosaicism by overexpressing genes or
knocking down mRNA with RNAi [9–12]. Specific tissues can be
targeted by injecting the virus directly into the desired site, or
transgenes can be used to specifically direct infection or expression
to certain tissues. For example, the RCAS/TVA transgenic system
allows for higher specificity of mutation through transgenic
expression of the TVA receptor, which is needed for infection
[13]. This elegant system has been used to study development as
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lines can be used to direct expression of lentivirus transgenes, as
recently utilized to model glioma [18]. The lentiviral approach has
the added benefits of being able to infect non-dividing cells and
carry larger DNA payloads [10,19,20]. Furthermore, extensive
libraries of cDNA or shRNA constructs are commercially available
in lentiviral backbones, which allows for rapid implementation and
facilitates forward genetic screens.
Transposons and the wC31 Integrase for Somatic
Transgenesis
The advent of in vivo transfection and electroporation to
introduce plasmid DNA in mammalian tissues has allowed
researchers to rapidly study gene function in the soma, as reviewed
in [21–23]. Combining these gene delivery technologies with
integrase or DNA cut-and-paste transposon systems allows for
rapid and stable introduction of transgenes. In the case of the
bacteriophage wC31 integrase system, plasmid DNA containing
an attB site is transferred by the integrase into pseudo-attp sites in
the mammalian genome [24]. The specific integration of plasmid
DNA into a limited number of pseudo-attp sites by wC31 integrase
is appealing for gene therapy approaches, as it reduces the chance
of undesired phenotypes like cancer development due to inser-
tional mutation [25]. For transposon-mediated gene transfer, the
gene(s) are simply flanked in a plasmid by transposon end
sequences and are introduced in trans with transposase to induce
transposition into the target cell genome. Modified Sleeping Beauty
(SB) and piggyBac (PB) transposon/transposase systems have been
used to mediate stable integration and expression of transgenes in
human cells and mice [26–32]. This strategy has been adapted to
rapidly model brain tumors [33] and test gene therapy approaches
in mice [28,34–36]. Thus, the wC31 integrase and transposon
tools can be rapidly constructed and implemented to efficiently
integrate DNA into somatic cells.
Thesuperiortranspositionefficiencyandcargocapacityofthe PB
transposon make it an ideal tool for gene manipulation in the soma.
The PB transposon system can transpose up to 10 kb of payload
without a significant drop in transposition activity [26]. This large
payload size allows for the combination of several cDNAs or RNAi
hairpins to be combined into one construct. Such a strategy has
been used to express multiple transcription factors in one PB
transposon to reprogram differentiated fibroblasts into induced
pluripotent stem (IPS) cells [37]. The unique ability of the PB
transposon to excise from the genome without leaving a mutation
also allows the transgene to be removed cleanly [37]. Furthermore,
it is possible to transpose multiple transposons into the same cell,
further enhancing the sophistication that can be incorporated into
the genetic manipulation [38,39]. The PB system, like lentiviral
constructs, will be useful in not only modeling disease, but also for
dissecting molecular mechanisms (Figure 1). An immediate applica-
tionwould be to validate the increasing number of candidate cancer
genes being identified by high-throughput sequencing and copy
number analysis of human tumors [40–47]. In contrast, the tradi-
tional production of a murine transgenic or knockout allele for each
one of these candidate genes in a similar effort would be extremely
costly and time-consuming.
Somatic Transgenesis of Human Tissues
Although mouse genetics and in vitro cell culture have been
successful experimental surrogates for human disease, studying
human cells in an in vivo environment is ideal. This can be
accomplished by transplanting human cells into mice or rats to
study developmental or disease processes. Such xenograft trans-
plants have been widely used to model cancer as reviewed in [48–
50]. However, a strategy involving the xenografting of normal
human cells to develop chimeric rodents first, and then the
induction of disease causing mutations would be much more
attractive to study pathogenesis. Researchers are actively working
to improve humanized models by increasing the engraftment and
function of human cells into mouse tissues [51–53].
The ability to reprogram differentiated cells to embryonic stem
cell–like IPS cells as first reported by the Yamanaka group [54] has
opened up new avenues for personalized cellular therapies. These
stem cells have the potential to serve as a source to replace
damaged, diseased, or aged tissues. Investigators have performed
proof-of-principle experiments in the mouse and rat to treat a
variety of degenerative conditions by cellular transplantation of
IPS or cells derived from IPS cells including: sickle cell anemia
[55], spinal cord injury [56], hemophilia [57], diabetes [58], and
Parkinson’s disease [59]. Building upon the mouse experiments,
IPS cells have been produced from normal and diseased human
cells [60–62]. These disease-specific IPS cells could be used as
donor cells to engraft for humanized mouse models.
Patient-derived disease-specific IPS cells are a perfect source of
material to genetically dissect disease. Inducible transgenes can be
introduced into these cells before engraftment into recipient mice
such that the molecular mechanism of the disease could be studied
in an in vivo environment. The PB transposon is ideally suited for
Table 1. Genetic Tools for Generating Mutant Clones and Somatic Mutagenesis in Mice.
Tool Applications
Cre/loxP Tissue-specific gene deletion, mutation, or expression with possible temporal control with Cre-ER. Mitotic
recombination to produce homozygous mutation or genomic rearrangements in specific tissues. Also used for
lineage tracing.
Flp/Frt Tissue-specific gene deletion, mutation, or expression with possible temporal control. Mitotic recombination to
produce homozygous mutation or genomic rearrangements in specific tissues. Also used for lineage tracing.
Less efficient than Cre/loxP in mouse.
Tet Tissue-specific and reversible gene expression.
wC31 integrase Somatic transgenesis targeted to pseudo-attp sites.
Lentivirus/Retrovirus Somatic transgenesis and insertional mutagenesis in hematopoietic and mammary tissues.
Sleeping Beauty transposon Somatic transgenesis and insertional mutagenesis with mutational footprint and high local hopping.
Advantageous for multigenic phenotypes and saturating mutations in genomic regions.
piggyBac transposon Somatic transgenesis and insertional mutagenesis without mutational footprint.
doi:10.1371/journal.pgen.1002110.t001
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to activate or repress cellular pathways to test the effect on disease
progression. Rats would also be an attractive host for future
models because of their well-studied pharmacological metabolism.
Such experimental models will likely be ideal to identify thera-
peutic targets genetically and then to test drugs in preclinical trials.
Screening for Disease-Associated Phenotypes
with Somatic Mutagens
Forward genetic screens, a phenotypic approach for screening
mutants without a priori assumptions of the molecular nature of
the affected genes, has been a powerful tool in lower organisms to
map genes responsible for a variety of phenotypes. In mice,
somatic forward genetic screens allow investigators to screen
many genes in one animal by mosaic mutagenesis, thus saving time
and money. To date, such somatic screens have been limited to the
identification of genes involved in cancer, but the development of
new genetic tools has now made screening for other phenotypes
possible.
In Vivo RNAi Screens
Loss-of-function screens have been performed in vivo with viral
RNAi libraries [63–65]. These screens involve isolating progenitor
cells, transducing with an RNAi library, and transplanting the cells
back into mice. The screens have successfully identified novel
tumor suppressors in the development of hepatocellular carcinoma
and leukemia. Unfortunately, not all tissues are currently amena-
ble to such transplantation protocols, but future improvements to
the efficiency of in vivo lentiviral transduction or transposon
introduction may facilitate screens in other tissues. As a result,
screening systems that do not rely on exogenous gene delivery are
currently more broadly applicable for in vivo forward genetic
screens.
Insertional Mutagenesis with Retrovirus
To date, the most widely used forward genetic strategy in the
mouse has been insertional mutagenesis with replication-compe-
tent retroviruses. These retroviruses have been used as a mutagen
to identify genes involved in cancer formation. The insertion of the
retroviral provirus into the host genome can cause mutation by
disrupting a gene sequence, by upregulating endogenous tran-
scription from the viral LTR, or by producing hypomorphic alleles
by inducing missplicing or alternative polyadenlation from the
provirus. The provirus also serves as a tag to identify the insertion
site and genes affected by PCR strategies. Thus, insertional muta-
genesis with retrovirus mutates and tags genes, which allows rapid
identification of causative mutations [66]. Indeed, many candidate
genes identified in these screens have been confirmed to be bona
fide cancer genes as reviewed in [67]. Modifier screens have also
revealed cooperation between distinct oncogenic pathways
[68,69]. Although retroviral mutagenesis is a validated forward
genetic tool, its broad utility is limited due to the fact that the tissue
selectivity of the retroviral mutagen limits these screens to
hematopoietic and mammary tissues.
Insertional Mutagenesis with Transposons
Transposon insertional mutagenesis (TIM) is a powerful tool for
inducing and identifying mutations of interest and has been
utilized with great effect in many organisms, from the bacterium to
the fruit fly Drosophila melanogaster [70,71]. The SB and PB DNA
transposons have been developed for germline TIM in mice
[26,72–75]. TIM systems allow the induction and identification of
mutations much like retroviral insertional mutagenesis, but with
Figure 1. Somatic phenotypes like cancer can be modeled and genetically dissected with transposon mutagenesis. Potential
oncogenic pathway to be interrogated with candidate oncogene X and effector Y in red (left). Depiction of PB transposon construct for verifying
oncogene X (center). Yellow arrows detail transposon arms. Promoters are depicted by blue pointed boxes. Gene X is indicated by red box and
luciferase marker is indicated by green box. To test if effector Y is involved in the oncogenic pathway, an shRNA cassette to knockdown gene Y is
represented by the red box (right). The transposons are co-transfected or electroporated with PBase (lower yellow box) to stably integrate the
transposon construct into the mouse cells. The green cells in the mouse indicate luciferase positive cells expressing the transposed construct, which
are monitored for the tumor formation.
doi:10.1371/journal.pgen.1002110.g001
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bipartite system consists of a transgenic line of non-autonomous
mutagenic transposons and a line expressing the transposase,
which promotes transposition [76]. Application of TIM in the
mouse germline enables collections of mutant animals to be
rapidly produced simply by breeding [26,72]. In fact, a large-scale
germline insertional mutagenesis with the PB transposon has
already produced more than 5,000 mouse lines, each with a
different gene mutated and a broad range of phenotypes (X. Wu
and T. Xu, unpublished data; http://idm.fudan.edu.cn/PBmice).
Furthermore, a Blm-deficient background can be used to increase
the rate at which transposon insertions are converted from
heterozygous to homozygous for rapid induction of recessive
mutations [77]. The success of germline TIM in decoding gene
and regulatory element function indicates that the strategy can be
applied to the soma for rapid and efficient forward genetic screens.
Somatic forward genetic screens have the potency to interrogate
thousands of genes for a wide range of phenotypes in a single
animal. This has been illustrated by the successful application of
TIM in somatic tissues for cancer gene discovery with SB and PB
[78–83]. These screens have identified known human cancer
genes and identified new players, thus confirming TIM as a viable
technology for mapping mutations associated with somatic
phenotypes. The induction of multiple tumors per mouse also
reduced the number of animals required to identify candidate
genes. By constructing latent transposase alleles with the Cre
system, specific somatic tissues have also been directly targeted for
screens [84–86]. With the proven success of the SB and PB systems
in interrogating cancer development, it is likely that TIM can be
applied to other developmental and disease processes.
The PB transposon has distinct advantages that make it an
attractive tool for applying somatic mutagenesis for other
phenotypes. First, PB has high transposition efficiency and can
mobilize large DNA payloads [26,31,87,88]. This allows for the
creation of highly mutagenic transposons and therefore insertional
screens to be performed with one or several copies of the
transposon. Fewer transposons per cell is especially helpful in
identifying causative mutations, because there will be less
background or ‘‘bystander’’ insertions. The larger DNA payload
also allows for the inclusion of fluorescent or bioluminescent
markers for identifying mutated cells. Second, PB does not leave a
footprint or mutation after excision like other transposons, so a
direct correlation between insertion and the phenotype can be
made [26,89,90]. However, a mutational footprint may be
advantageous for inducing phenotypes that require multiple
mutations as evidenced by efficient cancer induction with SB
[78–82]. Third, the majority of PB insertions are genome wide
compared to the extensive local hopping (transposon reinsertion
close to original site) found with SB [26,83]. Although local
hopping is advantageous for saturating mutagenesis at certain
genomic regions [91], it complicates the identification of causative
mutations and contributes to the formation of genomic rearrange-
ments [92]. Thus, the high efficiency of mutagenesis and ease of
mapping causative mutations makes PB desirable for gene
discovery in developmental and disease processes.
Theoretically, transposon mutagenesis can be performed in any
tissue or cell type and applied to any phenotype. However, while
tumors are readily identifiable, locating mutant clones is a prere-
quisite for screening and analyzing many other somatic phenotypes.
Visibly marking mutant somatic clones has been employed in
Drosophila, zebrafish, and mice and demonstrated to have tremendous
utility in analyzing a variety of clonal behaviors in vivo [93–97].
Consequently, a somatic TIM system that incorporates the ability to
track mutagenized cells would be ideal in somatic screens for
phenotypes other than tumor formation. We have recently exploited
PB’s unique properties to develop a highly efficient, Cre-inducible
TIM system and have demonstrated that tracking mutant clones with
visible markers allows detection of altered cellular proliferation and
infiltration, among other phenotypes induced by insertional mutation
( S .L a n d r e t t e ,J .C o r n e t t ,T .N i ,M .B o s e n b e r g ,a n dT .X u ,
unpublished data). Thus, TIM will likely be employed in future
studies to identify novel players in mammalian disease and
developmental pathways in vivo. Exciting areas for interrogation
include immunology, neurobiology, and cancer metastasis.
Figure 2. Screening for phenotypes in humanized mice with patient-derived IPS cells. IPS cells are first created from a patient. A mutator
transposon containing mutagenic elements (red box) and a GFP marker (green box) and an inducible PBase construct (utilizing the Cre-ER/lox or Tet
system) is introduced into patient-derived IPS cells. Green cells indicate GFP expression from the stably integrated mutator transposon(s). The cells
are then introduced into the mouse tissue by injection (syringe). Next, transposase activity is induced, which mobilizes the mutagenic transposon,
resulting in insertional mutation. Finally, the mice are screened for the desired disease or developmental phenotype.
doi:10.1371/journal.pgen.1002110.g002
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The next step would be to perform TIM screens in humanized
mice such that disease phenotypes could be genetically interrogated
in human cells in vivo. A TIM system consisting of multiple copies of
a mutagenic transposon and an inducible transposase could be stably
introduced into human IPS cells by transfection and selection. The
cells would then be introduced into a humanized mouse and screen-
ed for disease or developmental phenotypes (Figure 2). Beyond
inducing disease, it is also possible to screen for reversion of disease
phenotypes, which will be particularly useful in identifying relevant
targets for developing therapeutics. For example, IPS cells could be
generated from a patient with a neurodegenerative disease. These
cells could be introduced into a humanized mouse and mutagenized
with a TIM system. Clones of neurons that survive in the mouse
tissue and do not degenerate could be isolated and the transposon
insertions mapped. The insertional mutations identified likely would
reveal novel pathways involved in neurodegeneration that may be
amenable to therapeutic targeting. Thus, somatic mutagenesis has
the potential for unraveling the complexities of disease processes in
human cells that are difficult to experimentally query in vitro or
through human genome sequencing.
Conclusion
In summary, recent technological advancements in mouse
genetics have now provided opportunities to somatically interro-
gate the mouse and human genome that have previously only been
possible in non-mammalian genetic model organisms. Great strid-
es have been made in modeling somatic mosaicism, humanizing
mice, and forward genetic screening. Moving forward, lentiviral
and DNA transposon systems should be incredibly powerful in
modeling and dissecting developmental and disease processes due
to their ability to efficiently stably integrate large payloads of
genetic sequence. Combining these genetic tools with humanized
mice allows investigators to genetically manipulate human cells in
vivo, which should push the boundaries of human biology. Fur-
thermore, mammalian forward genetics is now at a point where
novel causative mutations in cancer and beyond can be mapped.
The advent of highly efficient TIM systems like PB allows genome-
wide screens to be performed in small cohorts of mice. Thus,
individual investigators now have the screening power to interro-
gate mammalian phenotypes in vivo. It is likely that screens will
soon discover mutations that can revert disease phenotypes, which
would accelerate the identification of new therapeutic avenues.
The mouse continues to be the model of choice for in vivo
verification and advances in somatic mutagenesis are evolving the
mouse as an indispensable tool for gene discovery.
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